Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Tim McCormick who wrote (77389)	3/9/2000 1:35:00 PM
From: Michael Bakunin	Respond to of 132070

Curious, I tracked down this document: research.ml.com Some highlights: "series of one-security indices in which the current on-the- run issue for each stated maturity remains in the index until the date a new one is auctioned and settles." "series of off-the-run run indices each comprised of a basket of securities that fall within a targeted maturity range of selected points on the yield curve" Looks like I was comparing apples and oranges -- an on-the-run 5-year vs. off-the-run baskets. Oops. At least I know more about bond index construction and calculation now. -g-, -mb

To: Tim McCormick who wrote (77389)	3/9/2000 1:55:00 PM
From: andy	Respond to of 132070

To Mike (not Tim, sorry I don't know how to change it): Have you looked into the possibility of undervalued, aspiring biotechs in that heavily taxed, giant refrigerator to the north of the US. Something tells me these people are cloistered in their labs trying to push the pharma envelope further. They have a similar underlying ethic and drive, but are ready to strive a shade harder inside their labs just to stay out of the bitter cold and to stay ahead of their governments voracious tax regimen. Recent years have shown a pattern: the Canadian public biotechs conduct university assisted research with almost all their money going into the lab and the researchers retained like starving missionaries. Then when their microscopes reveal something promising, the upstarts somehow merge easily into the US scene and the Canadian penny company swiftly rises into double digit dollars with a US premium, so it goes from incubation to success! More than two dozen of these low price companies exist. Admittedly I have only been tracking three: GNS and IZP on the TSE, and NRT on the CDNX, but there are others. What say you on the prospects of these frozen seed companies? -OT--Are you in any way related in more attributes than brightness to our remarkable columnist, James Burke, who is every month published in the Scientific American Journal?